Reactivation of Varicella Zoster virus in HIV infection. Actual issues

Abstract

The article presents current views on epidemiology, clinical manifestations, and ways of the prevention infection caused by Varicella Zoster virus in HIV-infected patients.

Keywords

Varicella zoster virus / HIV infection / Varicella zoster virus / shingles

References

[1] Zanoni B.C., Gandhi R.T. Update on opportunistic infections in the era of effective antiretroviral therapy. Infect. Dis. Clin. N. Am. 2014; 28 (3): 501-18.

[2] Shin B.S., Na C.H., Song I.G., Choi K.C.. A case of human immunodeficiency virus infection initially presented with disseminated herpes zoster. Ann. Dermatol. 2010; 22: 199-202.

[3] Shashikant Malkud, Santosh M Patil. Disseminated cutaneous herpes zoster in a patient with uncontrolled diabetes mellitus. J. Clin. Diag. Res. 2015; 9 (7): 1-2.

[4] Mehta S.K., Tyring S.K., Gilden D.H., Cohrs R.J., Leal M.J., Castro V.A., Feiveson A.H. et al. Varicella zoster virus in saliva of patients with herpes zoster. J. Infect. Dis. 2008; 197: 654-7.

[5] Cohrs R.J., Mehta S.K., Schmid D.S., Gilden D.H., Pierson D.L. Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts. J. Med. Virol. 2008; 80: 1116-22.

[6] De La Blanchardiere A., Rozenberg F., Caumes E., Picard O., Lionnet F., Livartowski J. et al. Neurological complications of varicella-zoster virus infection in adults with human immunodeficiency virus infection. Scand. J. Infect. Dis. 2000; 32: 263-9.

[7] Vafai A., Berger M. Zoster in patients infected with HIV: a review. Am. J. Med. Sci. 2001; 321: 372-80.

[8] Gershon A.A., Mervish N., LaRussa P., Steinberg S., Lo S.H., Hodes D. et al. Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J. Infect. Dis. 1997; 176: 1496-500.

[9] Нагибина М.В., Мартынова Н.Н., Преснякова О.А., Вдовина Е.Т., Груздев Б.М. Особенности клиники и лечения поражений кожи при ВИЧ-инфекции. Лечащий врач. 2015; (2): 4-6.

[10] Burke D.G., Kalayjian R.C., Vann V.R., Madreperla S.A., Shick H.E., Leonard D.G. Polymerase chain reaction detection and clinical significance of varicella-zoster virus in cerebrospinal fluid from human immunodeficiency virus-infected patients. J. Infect. Dis. 1997; 176: 1080-4.

[11] Corti M., Villafane M., Vittar N., Banco M., Priarone M. et al. Meningoencephalomyelitis with vasculitis due to varicella zoster virus: a case report and review of the literature. Rev. Inst. Med. Trop. Sao Paulo. 2015; 57 (6): 505-8.

[12] Gilden D., Cohrs R.J., Mahalingam R., Nagel M.A. Neurological disease produced by varicella zoster virus reactivation without rash. Top. Microbiol. Immunol. 2010; 342: 243-53.

[13] Ljungman P., Lönnqvist B., Gahrton G., Ringdén O., Sundqvist V.A., Wahren B. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J. Infect. Dis. 1986; 153: 840-7.

[14] Birlea M., Arendt G., Orhan E., Schmid D.S., Bellini W.J., Schmidt Ch. et al. Subclinical reactivation of varicella zoster virus in all stages of HIV infection. J. Neurol. Sci. 2011; 304 (1-2): 22-4.

[15] Nacher M., Basurko C., Adenis A., Gaubert-Marechal E., Mosnier E. et al. Predictive Factors of Herpes Zoster HIV-Infected Patients: Another Adverse Effect of Crack Cocaine//Published online 2013 Nov 11. doi: 10.1371/journal.pone.0080187 PMCID: PMC3823845

[16] Wilkin T., Lee J.Y., Lensing S.Y. et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J. Infect. Dis. 2010; 202 (8): 1246-53.

[17] Yi-Chieh Lee, Chien-Ching Hung, Mao-Song Tsai, Jun-Yu Zhang, Pei-Ying Wu et al. Incidence and risk factors of herpes zoster in human immunodeficiency virus-positive patients initiating combination antiretroviral therapy in Taiwan. J. Microbiol., Immunol. and Infection. 2016: 1-7.

[18] Buchacz K., Armon C., Palella F.J. et al. CD4 Cell Counts at HIV Diagnosis among HIV Outpatient Study Participants, 2000-2009. AIDS research and treatment. 2012: 869 841. [PMC free article] [PubMed].

[19] Mocroft A., Furrer H.J., Miro J.M. et al. The incidence of AIDSdefining illnesses at a current CD4 count >/= 200 cells/muL in the post-combination antiretroviral therapy era. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013; 57 (7): 1038-47. [PubMed].

[20] Buchbinder S.P., Katz M.H., Hessol N.A. et al. Herpes zoster and human immunodeficiency virus infection. J. Infect. Dis. 1992; 166 (5): 1153-6.

[21] Son M., Shapiro E.D., LaRussa P. et al. Effectiveness of varicella vaccine in children infected with HIV. J. Infect. Dis. 2010; 201 (12): 1806-10.

[22] Taweesith W., Puthanakit T., Kowitdamrong E. et al. The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 2011; 30 (4): 320-4.

[23] Aberg J.A., Gallant J.E., Ghanem K.G., Emmanuel P., Zingman B.S., Horberg M.A. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin. Infect. Dis. 2014; 58 (1): 1-34.

[24] Benson C., Hua L., Andersen J. et al. ZOSTAVAX is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebocontrolled trial. In: The 19th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; 2012: Abstract #96.

RIGHTS & PERMISSIONS

Eco-vector